News Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer.
News Genmab agrees $8bn takeover of cancer biotech Merus Genmab continues its shift from out-licensing drugs to developing its own drugs with an $8bn deal to buy Merus and its head and neck cancer therapy.
News Nykode changes tack after Roche exits partnership Hit by the loss of a partnership with Roche's Genentech unit last year, Norway's Nykode has narrowed its R&D focus.
News ASCO 25: Merus bispecific scores again in HNSCC For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye.
News Can Keytruda finally break into early head and neck cancer? The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.
News NHS pilots iPhone app to rule out throat cancer NHS England has started a pilot trial of an iPhone app and device combination that could be used by nursing staff to speed up reviews of suspected throat cancer.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
